Macquarie Group
AMLX icon

Macquarie Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Macquarie Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,528
Closed -$4.8K – 1662
2024
Q2 		$4.8K Buy
+2,528
New +$4.9K ﹤0.01% 1717

Other funds holding AMLX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Macquarie Group's AMLX Position: Q3 2024 in Review

Macquarie Group sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 2,528 shares — an estimated $4.8K sold.

Macquarie Group first reported a position in AMLX in Q2 2024 and held it in 1 quarter. The position peaked at $4.8K in Q2 2024. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

  • Macquarie Group reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 2,528 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $4.8K.
  • Macquarie Group first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Macquarie Group's Amylyx Pharmaceuticals position peaked at $4.8K in Q2 2024.
  • 110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.